“Efficiency equals speed” for hVIVO’s Dr Andrew Catchpole

Up next in our exclusive series of Congress Conversations from the Barcelona event we are delighted to share an interview with Dr Andrew Catchpole, hVIVO. He joined us at the Congress for a presentation and a panel, sharing his insights on human challenge models. We were glad that Dr Catchpole was happy to return for another conversation after our first meeting in Washington; you can watch the earlier interview here. We are grateful to Dr Catchpole for his time and hope you enjoy the interview!

Introducing Dr Catchpole

As Dr Catchpole states, he is Chief Scientific Officer at hVIVO. The company describes itself as a “rapidly growing specialist contract research organisation” and “the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials”.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO to hold AGM on 13 May 2024

    hVIVO plc (LON:HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has confirmed that the Company’s Annual Report and Accounts for the year ended

    hVIVO plc

    Hvivo reports 44% Rise in earnings and Record Year in 2023

    Pharmaceutical services firm Hvivo, formerly Open Orphan, reported a 44pc rise in earnings in 2023 in a “record year across all financial and operational metrics.” Earnings before interest, taxes, depreciation and amortisation (Ebitda) increased to £13m

    hVIVO plc

    hVIVO Investor Conference

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,